Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.
Morning Overview on MSN
How science and luck sparked a radical new era in schizophrenia treatment
The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a fundamentally new mechanism of action in more than half a century. Built on ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Cobenfy (xanomeline/trospium chloride; formerly KarXT) was ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...
Schizophrenia is a chronic psychiatric disorder that requires lifelong management, with consistent medication adherence essential to prevent relapse and disability. Counseling that emphasizes empathy, ...
Machine learning can predict many things, but can it predict who will develop schizophrenia years before the average ...
The health secretary claimed twice earlier this month that the high-fat, low-carb keto diet can "cure" mental illness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results